Own CSL shares? Here's what's in the development pipeline

Research into messenger RNA (mRNA) has ramped up since the onset of COVID-19.

| More on:
Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have gained 7% since the S&P/ASX 200 Index (ASX: XJO) listed biotech share held its annual research and development (R&D) briefing on 19 October.

Below, we take a look at what's in that pipeline.

What is the ASX 200 biotech company developing?

As the Motley Fool reported on the day, CSL invested more than US$1 billion (AU$1.35 billion) into R&D in the 2021 financial year. That money supported 6 therapeutic areas, 4 scientific platforms, and 2 businesses.

Breaking those down, the 6 therapeutic areas are:

  • Immunology,
  • Hematology,
  • Respiratory,
  • Cardiovascular and metabolic,
  • Transplant, and
  • Influenza

The 4 scientific platforms are:

  • Plasma fractionation,
  • Recombinant technology,
  • Cell and gene therapy, and
  • Vaccines

And the 2 businesses are:

  • CSL Behring, and
  • Seqirus

Among the highlights, CSL announced that its Seqirus business was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services.

The multi-year contract centres around CSL's adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and next-generation self-amplifying mRNA for seasonal and pandemic influenza (sa-mRNA). CSL intends to develop 2 influenza A(H2Nx) vaccine candidates for assessment in a Phase 1 clinical study. The end goal is to help communities stay safe in the event of an influenza pandemic.

CSL also announced a new collaboration with the Walter and Eliza Hall Institute for Medical Research in Australia to create a Centre for Biologic Therapies.

Commenting on that collaboration and what it means for CSL's development pipeline, CSL's Senior Vice President Andrew Nash said:

CSL's antibody library will be the engine room of biologics discovery at the Centre and, importantly, the knowledge transfer between the two organizations and the utilization of shared assets, resources, and facilities will be of great value.

This expansion of our relationship with WEHI will help ensure that the long-term investment of public funds into medical research in Australia is translated into both a benefit for patients and the Australian economy.

How have CSL shares been performing?

CSL shares have been on a bit of a rollercoaster over the past 12 months. It's a ride that has left them 3% in the green. By comparison, the ASX 200 has gained 17% over the same period.

Over the past month, CSL shares are up 8%.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »